Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand
by Julia Kollewe from World news | The Guardian on (#6NRKE)
Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy
Novo Nordisk is to invest more than $4bn (3.2bn) in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic.
Denmark's biggest pharmaceuticals company said it would spend $4.1bn building a second filling and finishing facility in Clayton, North Carolina, one of the biggest manufacturing investments in its history. Its drugs are injected by users once a week, and come in pre-filled pens.
Continue reading...